Hugues Lecat tapped as chair, CEO of Ethypharm

> Hugues Lecat has been appointed chairman and CEO of the management board of the pharmaceutical company Ethypharm. Release

> BioPhausia CEO Claes Thulin is leaving his post in order to pursue entrepreneurial activities. Release  

> Intellipharmaceutics International has appointed Graham Neil as CFO and VP, finance. Release  

> Merck has tapped Bridgette Heller as EVP and president, consumer healthcare. Release  

> Aton Pharma announced that Wayne Mulcahy has joined the company as VP, clinical operations. Release  

> Oramed Pharmaceuticals expands scientific advisory board with the appointment of John Amatruda. Release

> Novavax board of directors has reported that Stanley Erck has been elected executive chairman. Release  

> Daiichi Sankyo names Jay Feingold as VP of medical affairs. Release

> Amarin has named Jan van Heek to its board of directors as a non-executive director. As part of his board role, van Heek has been appointed chairman of the company's audit committee. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.